InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.185 0.05 (4.41%)+
Announcement
Release
3 Dec 2025 9:33AM
Price at Release
$1.135
Full Release
download
Summary
OncoSil Medical Limited's interim analysis from the OSPREY registry shows a promising overall survival profile for patients with unresectable locally advanced pancreatic cancer (LAPC) treated with the OncoSil™ device alongside gemcitabine-based chemotherapy. The OSPREY registry, representing data from 19 centers in Europe, reported a median overall survival of 20.6 to 22.0 months for first-line patients, marking a significant improvement over historical data. The study also noted a high local disease control rate and minimal adverse device events. These findings are consistent with previous studies, such as the PanCO trial, and support OncoSil’s targeted approach to enhancing radiation dose delivery directly into tumors. The data are set to be presented at the ESGE Days congress in May 2026.
Key Points
  • OSPREY registry shows improved survival with OncoSil™ device.
  • Median overall survival of 20.6 to 22.0 months for first-line patients.
  • Significant improvement compared to historical data of 12.7 to 18.8 months.
  • 91.7% local disease control rate at 12 weeks for first-line patients.
  • Minimal adverse device events reported in OSPREY study.
  • OncoSil™ approved in over 30 countries, including EU and UK.
  • Findings to be presented at ESGE Days congress in May 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.